# LCS16 vs. COC User Satisfaction and Tolerability Study

> **NCT03074045** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 145 (actual)

## Conditions studied

- Contraception

## Interventions

- **DRUG:** Levonorgestrel (Kyleena, BAY86-5028)
- **DRUG:** Ethinyl estradiol and drospirenone (Yarina, BAY86-5131)

## Key facts

- **NCT ID:** NCT03074045
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-13
- **Primary completion:** 2018-09-03
- **Final completion:** 2022-08-05
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03074045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03074045, "LCS16 vs. COC User Satisfaction and Tolerability Study". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03074045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*